Amanda R. Muñoz

Amanda R. Muñoz

Auto-generated profile, based on publicly available information

Amanda R. Muñoz

Department of Urology, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Cancer Letters
Verified
Journal Article
Open access
DCDivya Chakravarthy
Divya Chakravarthy
AMAmanda R. Muñoz
Amanda R. Muñoz
ASAngel Su
Angel Su
RHRosa F. Hwang
Rosa F. Hwang
BKBrian R. Keppler
Brian R. Keppler
PKPratap Kumar
Pratap Kumar
Reciprocal interaction between pancreatic stellate cells (PSCs) and cancer cells (PCCs) in the tumor microenvironment (TME) promotes tumor cell survival and progression to lethal, therapeutically resistant pancreatic cancer. The goal of this study was to test the ability of Palmatine (PMT) to disrupt this reciprocal interaction in vitro and examine the underlying mechanism of interaction. We show that PSCs secrete glutamine into the extracellular environment under nutrient deprivation. PMT suppresses glutamine-mediated changes in GLI signaling in PCCs resulting in the inhibition of growth and migration while inducing apoptosis by inhibition of survivin. PMT-mediated inhibition of (glioma-associated oncogene 1) GLI activity in stellate cells leads to suppression (collagen type 1 alpha 1) COL1A1 activation. Remarkably, PMT potentiated gemcitabine's growth inhibitory activity in PSCs, PCCs and inherently gemcitabine-resistant pancreatic cancer cells. This is the first study that shows the ability of PMT to inhibit growth of PSCs and PCCs either alone or in combination with gemcitabine. These studies warrant additional investigations using preclinical models to develop PMT as an agent for clinical management of pancreatic cancer.

15 March 2014 in Oncotarget
Verified
Journal Article
Open access
PDF file
JGJingjing Gong
Jingjing Gong
AMAmanda R. Muñoz
Amanda R. Muñoz
DCDaniel Chan
Daniel Chan
RGRita Ghosh
Rita Ghosh
PKPratap Kumar
Pratap Kumar
The dismal 5-year survival (<5%) for pancreatic cancer (PanCA) underscores the need for developing effective therapeutic options. Recent studies from our laboratory have shown that Nexrutine® (Nx), a bark extract from Phellodendron amurense exhibits excellent anticancer activity in human pancreatic cancer cells through inhibition of inflammatory signaling via STAT3/NFκB/Cox-2. Given the apparent high oxidative stress and autophagic activity in pancreatic tumors, we investigated the potential of Nx to modulate autophagy, reactive oxygen species (ROS), and their crosstalk. Our results show that Nx inhibits autophagy and decreases ROS generation. Pharmacological inhibition of autophagy led to decreased ROS generation and proliferation with no significant effect on apoptosis. Further, using combination index analysis we also found that combination of late-stage autophagy inhibitor with Nx exhibited a moderate synergistic to additive effect. Additionally, genetic or pharmacological inactivation of STAT3 reduced LC3-II levels and expression indicating a possible role for STAT3 in transcriptional regulation of autophagy. Since both inflammatory and oxidative stress signaling activate STAT3, our data implicates that STAT3 plays a vital role in the regulation of autophagy through its contributions to the positive feedback loop between ROS and autophagy. Overall, our findings reveal an important role for STAT3/LC3/ROS in Nx-mediated anti-pancreatic cancer effects.

21 May 2016 in Molecular Carcinogenesis
Verified
Journal Article
Closed access
PDF file
JGJingjing Gong
Jingjing Gong
AMAmanda R. Muñoz
Amanda R. Muñoz
SPSubramanya Pingali
Subramanya Pingali
FPFlorastina Payton‐Stewart
Florastina Payton‐Stewart
DCDaniel E. Chan
Daniel E. Chan
PKPratap Kumar
Pratap Kumar

3 January 2020 in Communications Biology
Verified
Journal Article
Open access
PDF file
DTDinesh Thapa
Dinesh Thapa
Shih-Bo HuangShih-Bo Huang
Shih-Bo Huang
AMAmanda R. Muñoz
Amanda R. Muñoz
XYXiaoyu Yang
Xiaoyu Yang
RBRoble G. Bedolla
Roble G. Bedolla
Rita GhoshRita Ghosh
Rita Ghosh
NAD[P]H:quinone oxidoreductase 1 (NQO1) regulates cell fate decisions in response to stress. Oxidative stress supports cancer maintenance and progression. Previously we showed that knockdown of NQO1 (NQO1low) prostate cancer cells upregulate pro-inflammatory cytokines and survival under hormone-deprived conditions. Here, we tested the ability of NQO1low cells to form tumors. We found NQO1low cells form aggressive tumors compared with NQO1high cells. Biopsy specimens and circulating tumor cells showed biochemical recurrent prostate cancer was associated with low NQO1. NQO1 silencing was sufficient to induce SMAD-mediated TGFβ signaling and mesenchymal markers. TGFβ treatment decreased NQO1 levels and induced molecular changes similar to NQO1 knockdown cells. Functionally, NQO1 depletion increased migration and sensitivity to oxidative stress. Collectively, this work reveals a possible new gatekeeper role for NQO1 in counteracting cellular plasticity in prostate cancer cells. Further, combining NQO1 with TGFβ signaling molecules may serve as a better signature to predict biochemical recurrence.

11 October 2017 in Current Pharmacology Reports
Verified
Journal Article
Closed access
PDF file
AMAmanda R. Muñoz
Amanda R. Muñoz
DCDivya Chakravarthy
Divya Chakravarthy
JGJingjing Gong
Jingjing Gong
GHGlenn A. Halff
Glenn A. Halff
RGRita Ghosh
Rita Ghosh
PKPratap Kumar
Pratap Kumar